Patent: 9,534,052
✉ Email this page to a colleague
Summary for Patent: 9,534,052
Title: | Reducing systemic regulatory T cell levels or activity for treatment of Alzheimer\'s disease |
Abstract: | A pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS that does not include the autoimmune neuroinflammatory disease, relapsing-remitting multiple sclerosis (RRMS), is provided. The pharmaceutical composition is for administration by a dosage regimen comprising at least two courses of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session. |
Inventor(s): | Eisenbach-Schwartz; Michal (Rehovot, IL), Baruch; Kuti (Rehovot, IL), Rosenzweig; Neta (Rehovot, IL) |
Assignee: | Yeda Research and Development Co. Ltd (Rehovot, IL) |
Application Number: | 15/212,231 |
Patent Claims: | see list of patent claims |
Details for Patent 9,534,052
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Merck Sharp & Dohme Corp. | KEYTRUDA | pembrolizumab | For Injection | 125514 | 09/04/2014 | ⤷ Try a Trial | 2034-03-12 |
Merck Sharp & Dohme Corp. | KEYTRUDA | pembrolizumab | Injection | 125514 | 01/15/2015 | ⤷ Try a Trial | 2034-03-12 |
Bristol-myers Squibb Company | OPDIVO | nivolumab | Injection | 125554 | 12/22/2014 | ⤷ Try a Trial | 2034-03-12 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |